AMIKACIN SULFATE INJECTION USP 500 MG / 2 ML
AMIKACIN (AMIKACIN SULFATE) : 500 MG / 2 ML · DIN 02481073 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is AMIKACIN SULFATE INJECTION USP?
AMIKACIN SULFATE INJECTION USP 500 MG / 2 ML contains AMIKACIN (AMIKACIN SULFATE) : 500 MG / 2 ML. It is listed in the Health Canada Drug Product Database under DIN 02481073, held by MARCAN PHARMACEUTICALS INC, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 01-Mar-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AMIKACIN SULFATE INJECTION USP used for?
Short-term treatment of serious infections (bacteremia, septicemia, respiratory, urinary tract, intra-abdominal, soft tissue) caused by susceptible gram-negative bacteria and Staph. aureus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02481073 |
|---|---|
| Brand name | AMIKACIN SULFATE INJECTION USP |
| Generic / active ingredient | AMIKACIN (AMIKACIN SULFATE) : 500 MG / 2 ML |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 500 MG / 2 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01GB06 AMIKACIN |
| AHFS class | 08:12.02 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Mar-2019 |
| Original market date | 2019-03-01 00:00:00 |
How is it administered?
Adults/Children/Neonates: 15 mg/kg/day divided into 7.5 mg/kg every 12 hours. Max 1.5 g/day. Treatment usually 7-10 days. Administer IM or IV (over 30-60 mins).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 30°C. Protect from light. Discard unused portion.
How is it supplied?
500 mg/2 mL available in single-use 2 mL Flip-Off glass vials, boxes of 10.
Contraindications
Known allergy to amikacin or any components; history of hypersensitivity or serious toxic reactions to aminoglycosides due to known cross-sensitivities.
Warnings and precautions
Potential for ototoxicity (vestibular/auditory) and nephrotoxicity. Risk of neuromuscular blockade and respiratory paralysis. Contains sodium bisulfite (allergic risk).
Is AMIKACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by OMEGA LABORATORIES LIMITED, last seen 12 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01GB06 AMIKACIN. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02486717 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02529459 |
| AMIKACIN SULFATE INJECTION USP | 250 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242971 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | HIKMA CANADA LIMITED | CANCELLED POST MARKET | DIN 02525909 |
| AMIKACIN SULFATE INJECTION | 250 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | DIN 02539535 |
| AMIKIN | 250 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00397415 |
| ERFA-AMIKACIN | 250 MG | SOLUTION | SEARCHLIGHT PHARMA INC | CANCELLED POST MARKET | DIN 02489147 |
| VPI-AMIKACIN | 500 MG / 2 ML | SOLUTION | VPI PHARMACEUTICALS INC | DORMANT | DIN 02506599 |
Who else supplies AMIKACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMIKACIN appears in 61 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.